|
Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
DelSite
Biotechnologies, Inc.
(OTC: DSII)
Digital
Angel Corporation
(AMEX:DOC)
Duska Therapeutics,
Inc.
(OTC:DSKA)
Elan
Corporation
(NYSE: ELN)
Galapagos NV
(Euronext:GLPGA)
Intercell AG
(VSE:ICLL)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Lpath, Inc.
(OTC:LPTN)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware
Information Systems, Inc. (NASDAQ: MEDW)
Pipex Pharmaceuticals,
Inc.
(OTC:PPXP.OB)
Quidel
(NASDAQ:QDEL)
Redpoint Bio Corporation
(OTC:RPBC)
XTLbio
(NASDAQ:XTLB)
VIA Pharmaceuticals,
Inc.
(NASDAQ: VIAP)
ZIOPHARM, INC.
(NASDAQ:ZIOP)
| |
Manhattan
Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires
and develops novel, high-value drug candidates primarily for the treatment
of dermatologic disorders. With a pipeline consisting of four clinical stage
product candidates, the company is currently developing Hedrin(tm), a novel,
non-insecticide treatment for pediculosis (head lice); Topical PTH (1-34)
for the treatment of psoriasis; Altoderm(tm) (topical cromolyn sodium) for
the treatment of pruritus associated with dermatologic conditions including
atopic dermatitis; and Altolyn(tm) (oral tablet cromolyn sodium) for the
treatment of mastocytosis.
COMPANY
NEWS |
COMPANY WEBSITE |SEC
FILINGS | STOCK
QUOTE
|